The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis
  • Tru Beauty is a salon distributor that services 40,000 salons across the U.S.
  • Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years
  • Cellmid is up four per cent on the market today and shares are trading for 13 cents per share

Cellmid (CDY) subsidiary, Advangen, has signed a distribution agreement with Tru Beauty Concepts for its anti-aging hair care products, évolis.

Tru Beauty is a salon distributor and national educator, servicing 40,000 salons through the United States.

Under the agreement, Tru Beauty will sell the évolis range to salons in northeast America for five years.

évolis will also be listed on the Salon Interactive portal, which is an e-commerce hub for hair salons across the U.S. This deal is expected to result in significant revenue growth in the U.S. business during the second half of the 2021 financial year.

CEO Maria Halasz says this agreement is a “game-changer.”

“Securing salon distribution will add scale to our U.S. expansion and growth ambitions for the brand,” she added.

The deal comes as consumer health services in the U.S. increased by 51 per cent to $626,000 over FY20.

Cellmid is up four per cent on the market this afternoon and shares are trading for 13 cents per share at 1:26 pm AEST.

CDY by the numbers
More From The Market Online
Molecules

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess…
US VA HQ

TrivarX flags US Veterans Affairs mental health trial – then halts trade for raise

TrivarX has halted shares ahead of a placement moments after just announcing a deal with the…
US flag

EZZ Life Sciences dips as company pushes manufacturing into US

EZZ Life Sciences (ASX:EZZ) fell -5% in early trades on Tuesday as the company flagged a…
The Market Online Video

Xanamem: Alzheimer’s breakthrough set for 2025, 2026

The search for an effective treatment for neurological conditions like Alzheimer’s disease remains one of the most urgent challenges in global healthcare.